Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 795-799

  Dunn, Theresa A ^a   Schmoll, Hans Joachim ^b   Grünwald, Viktor ^a   Bokemeyer, Carsten ^c   Casper, Jochen ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Amifostine; Antitumor activity; Cisplatin; Germ cell neoplasms; Human xenografts; Nude mice; WR 2721

Indexed keywords

ALKALINE PHOSPHATASE; AMIFOSTINE; AMINOTHIOL; CISPLATIN; PRODRUG; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER SIZE; CONTROLLED STUDY; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NON SEMINOMATOUS GERMINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TESTIS CANCER; XENOGRAFT;

EID: 0029860318     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00013     Document Type: Article

References (33)

1. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol). Clinical experiences. Semin Oncol 1994; 21(5) suppl 11: 8-15.
2. Calabro-Jones P, Fahey R, Smoluk G, et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23-7.
3. Nakamura J, Shaw LM, Brown DQ. Hydrolysis of WR-2721 by mouse liver cell fractions. Radiat Res 1987; 109: 143-52.
4. Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988; 48: 3641-7.
5. Utley JF, Seaver N, Newton GL, et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 1984; 10: 1525-8.
6. Calabro-Jones P, Aguilera J, Ward J, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988; 48: 3634-40.
7. Shaw LM, Glover D, Turrisi A, et al. Pharniacokinetics of WR-2721. Pharmac Ther 1988; 39: 195-201.
8. Treskes M, Boven E, Holwerda U. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992; 52: 2257-60.
9. Hustin J, Collette J, Franchimont P. Immunohistochemical demonstration of placental alkaline phosphatase in various states of testicular development and in germ cell tumours. Int J Androl 1987; 10: 29-35.
10. Andrews PW, Bronson DL, Wiles MV, et al. The expression of MHC antigens by human teratocarcinoma derived cell lines Tissue Antigens 1981; 17: 493-500.
11. Benham FJ, Andrews PW, Knowles BB, et al. Alkaline phosphatase isoenzymes as possible markers of differentiation in human testicular teratocarcinoma cell lines. Dev Biol 1981; 88: 279-87.
12. Casper J, Schmoll H-J, Schnaidt U, et al. Cell lines of human germinal cancer. Int J Androl 1987; 10: 105-13.
13. Harstrick A, Casper J, Schmoll HJ. Comparative antitumor activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. Int J Androl 1987; 10: 139-45.
14. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 1989; 63: 1079-83.
15. Dunn TA, Schmoll HJ, Grunwald V, Casper J. Preclinical activity of taxol in non-seminomatous germ cell tumor (NSGCT) cell lines and nude mouse xenografts. Paper submitted.
16. van der Wilt CL, van Laar JAM, Gyergyay FS, Smid K, Peters GJ. Biochemical modification of toxicity and the anti-tumor effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 1992; 28A: 2017-24.
17. Andrews PW, Banting G, Damjanov I, et al. Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 1984; 3: 347-361.
18. Glover D, Grabelsky S, Fox K. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1989; 16: 1201-04.
19. Ghiorghis A, Talebian A, Schein PS, et al. Effect of anticancer drugs against PA-I human ovarian cancer cells pretreated with the chemoprotective agent WR2721. Proc Am Ass Cancer Res 1992.
20. Treskes M, Boven E, van de Loosdrecht AA. Effects of the modulating agent WR2721 myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994; 30A: 183-7.
21. Douay L, Hu C, Giarratana M, et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849-33.
22. Valeriate F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330-1.
23. Millar JL, McElwain TJ, Clutterbuck RD, et al. The modification of melphalan toxicity in tumor bearing mice by S-2(3-aminopropylamino)-ethylphosphorothoic acid (WR 2721). Am J Clin Oncol 1982; 5: 321-8.
24. Korst AEC, Boven E, van der Vijgh WJF. Influence of amifostine on the platinum concentration in plasma and tumor tissue of nude mice treated with carboplatin. Ann Oncol 1994; 5 (suppl 5): S205.
25. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of chinese hamster ovary cells. Biochem Pharmacol 1995; 50: 489-96.
26. Shigematsu N, Schwartz JL, Gardina DJ. Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N″-(dithiode-2,1-ethanediyl)bis-1,3-propanediamine (WR.33278). Mutagenesis 1994; 9: 355-60.
27. Hasan R, Alam MK, Ali R. Polyamine induced Z-conformation of native calf thymus DNA. FEBS Lett 1995; 368: 27-30.
28. Van-den-Broeck D, Van-der-Straeten D, Van-Montagu M, et al. A group of chromosomal proteins is specifically released by spermine and loses DNA-binding activity upon phosphorylation. Plant Physiol 1994; 106: 559-66.
29. Thomas T, Gallo MA, Klinge CM, et al. Polyamine-mediated conformation perturbations in DNA alter the binfing of estrogen receptor to poly(dG-m5dC). poly(dG-m5dC) and a plasmid containing the estrogen response element. J Steroid Biochem Mol Biol 1995; 54: 89-99.
30. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecol Oncol 1993; 50: 147-58.
31. Bokemeyer C, Frank B, van Rhee J, et al. Peripheral neuropathy following cancer chemotherapy. Long term results in patients with curable neoplasms. Tumordiagn Ther 1993; 14: 232-7.
32. Bokemeyer C, Berger C, Kynast B, et al. Ototoxicity following therapy for testicular cancer. Eur J Cancer 1993; 29A (suppl 6): 1357.
33. Siegert W, Beyer J, Strohscheer I, et al. High dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell tumors - a phase I/II study. J Clin Oncol 1994; 12: 1223-31.